Verrica Pharmaceuticals Stock Current Valuation
| VRCA Stock | USD 0.72 0.01 1.37% |
Valuation analysis of Verrica Pharmaceuticals helps investors to measure Verrica Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of January 31, 2025, Enterprise Value Over EBITDA is expected to decline to -4.68. In addition to that, Enterprise Value Multiple is expected to decline to -4.68. Fundamental drivers impacting Verrica Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Verrica Pharmaceuticals' price fluctuation is abnormally volatile at this time. Calculation of the real value of Verrica Pharmaceuticals is based on 3 months time horizon. Increasing Verrica Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Verrica Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Verrica Stock. However, Verrica Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.72 | Real 1.37 | Target 3.33 | Hype 0.74 | Naive 0.49 |
The real value of Verrica Stock, also known as its intrinsic value, is the underlying worth of Verrica Pharmaceuticals Company, which is reflected in its stock price. It is based on Verrica Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Verrica Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Verrica Pharmaceuticals helps investors to forecast how Verrica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Verrica Pharmaceuticals more accurately as focusing exclusively on Verrica Pharmaceuticals' fundamentals will not take into account other important factors: Verrica Pharmaceuticals Company Current Valuation Analysis
Verrica Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Verrica Pharmaceuticals Current Valuation | 89.28 M |
Most of Verrica Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verrica Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Verrica Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Verrica Pharmaceuticals is extremely important. It helps to project a fair market value of Verrica Stock properly, considering its historical fundamentals such as Current Valuation. Since Verrica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verrica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verrica Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Verrica Current Valuation Historical Pattern
Today, most investors in Verrica Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verrica Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Verrica Pharmaceuticals current valuation as a starting point in their analysis.
Verrica Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Verrica Pharmaceuticals has a Current Valuation of 89.28 M. This is 99.38% lower than that of the Pharmaceuticals sector and 98.08% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.46% higher than that of the company.
Verrica Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verrica Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verrica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Verrica Pharmaceuticals by comparing valuation metrics of similar companies.Verrica Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Verrica Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verrica Pharmaceuticals from analyzing Verrica Pharmaceuticals' financial statements. These drivers represent accounts that assess Verrica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verrica Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 287.7M | 247.7M | 93.9M | 331.9M | 381.7M | 299.0M | |
| Enterprise Value | 312.3M | 275.4M | 61.2M | 307.9M | 354.1M | 283.5M |
Verrica Fundamentals
| Return On Equity | -20.6 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | 11.62 % | ||||
| Current Valuation | 89.28 M | ||||
| Shares Outstanding | 90.56 M | ||||
| Shares Owned By Insiders | 43.85 % | ||||
| Shares Owned By Institutions | 15.80 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Book | 238.54 X | ||||
| Price To Sales | 7.05 X | ||||
| Revenue | 5.12 M | ||||
| Gross Profit | (13.47 M) | ||||
| EBITDA | (62.2 M) | ||||
| Net Income | (67 M) | ||||
| Cash And Equivalents | 14.4 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 45.51 M | ||||
| Debt To Equity | 2.69 % | ||||
| Current Ratio | 1.25 X | ||||
| Book Value Per Share | (0.75) X | ||||
| Cash Flow From Operations | (38.58 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 3.33 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.46 | ||||
| Market Capitalization | 64.95 M | ||||
| Total Asset | 81.6 M | ||||
| Retained Earnings | (230.45 M) | ||||
| Working Capital | 60.51 M | ||||
| Net Asset | 81.6 M |
About Verrica Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verrica Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verrica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verrica Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:Check out Verrica Pharmaceuticals Piotroski F Score and Verrica Pharmaceuticals Altman Z Score analysis. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share | Quarterly Revenue Growth 27.445 | Return On Assets | Return On Equity |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.